TCL Archive Final Results from CLEOPATRA Phase III Trial Show Perjeta Increased OS 15.7 Months September 26, 2014
TCL Archive “The One Thing You Want From AN NCI Director: He Will Be Bound By The Facts” October 28, 1994
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Nine Saturation Program Planning Winners Names NCI May Reissue RFP Later This Year May 23, 1975
TCL Archive In Brief: Takeo Kakanaga Dies; President’s Cancer Panel to Meet Nov. 7; Young To Give Schwartz Lecture October 7, 1988
